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Abstract
Protein kinases have been found to possess two characteristic conformations in their activation-loops: the active DFG-in
conformation and the inactive DFG-out conformation. Recently, it has been very interesting to develop type-II inhibitors
which target the DFG-out conformation and are more specific than the type-I inhibitors binding to the active DFG-in
conformation. However, solving crystal structures of kinases with the DFG-out conformation remains a challenge, and this
seriously hampers the application of the structure-based approaches in development of novel type-II inhibitors. To
overcome this limitation, here we present a computational approach for predicting the DFG-out inactive conformation
using the DFG-in active structures, and develop related conformational selection protocols for the uses of the predicted
DFG-out models in the binding pose prediction and virtual screening of type-II ligands. With the DFG-out models, we
predicted the binding poses for known type-II inhibitors, and the results were found in good agreement with the X-ray
crystal structures. We also tested the abilities of the DFG-out models to recognize their specific type-II inhibitors by
screening a database of small molecules. The AUC (area under curve) results indicated that the predicted DFG-out models
were selective toward their specific type-II inhibitors. Therefore, the computational approach and protocols presented in
this study are very promising for the structure-based design and screening of novel type-II kinase inhibitors.
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Introduction
Human genome contains about 518 genes which encode
protein kinases (PKs) and account for approximately 2% of the
whole human genes [1]. This large protein family is responsible for
regulating nearly every aspect of the cellular activities through
protein phosphorylation. And unregulated PK activities often
cause severe human diseases, such as cancers, inflammation and
neuronal disorders etc. [2,3]. Indeed, the PK catalytic domains are
one of the most common domains in which mutations may lead to
human cancers. For such reasons, protein kinases have long been
regarded as one of the most important families of drug targets
[4,5,6].
Although the number of human PK family members is large,
the existing X-ray crystallographic structures showed that the
three-dimensional (3D) structures of their catalytic domains are
similar [7]. Typically, the catalytic domain of a PK consists of a
smaller N-terminal lobe (N-lobe) and a bigger C-terminal lobe (C-
lobe) [8]. And the ATP-binding site is located in a deep cleft
between these two lobes. The catalytic residues and the activation
loop that are crucial for phosphoryl transfer reaction are located in
the cleft. Almost in all PKs, at the N-terminal of the flexible
activation-loop there exists a conserved three-residue motif, Asp-
Phe-Gly (DFG). The conformational state of this motif has been
shown to be a determining factor to the PK activation [9,10]. In
the active state, the phenylalanine (Phe) side-chain occupies the
ATP-binding pocket, and the aspartate (Asp) side-chain is located
in the outside of the pocket (DFG-in conformation). When the so-
called ‘DFG-flip’ occurs, the Asp and Phe residues swap their
positions: the Asp side-chain rotates into the ATP-binding pocket,
and the Phe side-chain rotates out of the ATP-binding pocket
(DFG-out conformation), leading the PK to the inactive state
[10,11]. Some human kinases were shown to be able to adopt the
DFG-out conformation [12,13,14], and it was suggested that the
DFG-in and DFG-out conformations might actually co-exist in the
way of dynamic equilibrium [10].
Since a PK in the DFG-out conformation is inactive, it is very
interesting to develop inhibitors to specifically recognize the DFG-
out conformation [15,16]. Several inhibitors have already been
found to be able to bind to and stabilize the DFG-out inactive
forms of their kinase targets [17,18]. They have been shown to be
more specific and effective than those inhibitors which target the
active DFG-in conformation (i.e., type-I inhibitors) and therefore
were called type-II inhibitors [19,20,21]. One example is the anti-
cancer drug imatinib (Gleevec, Novartis), which specifically binds
to the DFG-out conformations of the tyrosine kinases BCR-ABL,
c-Abl, c-Kit and PDGFR [22,23,24,25]. And, as known, structure-
based drug design is a very important approach to the discovery of
novel type-II kinase inhibitors [16,26]. However, so far only a few
kinase DFG-out structures have been solved, and the structural
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of kinases is still lacking [27]. Currently, in the Protein Data Bank
(PDB), more than 70% of mammal kinase structures are in the
DFG-in conformation, and 22% are intermediate structures,
about 3% are apo-DFG-out structures which are type-II
incompatible [28]. This certainly poses a difficult problem for
employing the structure-based design approaches to the discovery
of novel type-II kinase inhibitors, because in this approach the
kinase DFG-out structures are one of the prerequisites. To address
this, it is necessary to develop computational methods which are
able to predict DFG-out structures using the large numbers of the
existing DFG-in structures.
Recently, Kufareva and Abagyan have already developed a
computational protocol for converting DFG-in structures of
various kinases into type-II bound state by deleting about six
residues of the activation-loop starting with the DFG-motif, i.e.,
the so-called DOLPHIN (deletion-of-loop Asp-Phe-Gly-in) models
[28]. The DOLPHIN models suggested that the main factor
affecting the binding of type-II inhibitors could be attributed to the
difference of the DFG motif and its neighbor residues between
DFG-in and DFG-out conformations. Inspired by this study, here
we present a new computational approach called activation-loop
remodeling method (ALRM) to predict the DFG-out inactive
conformations using the DFG-in active structures of PKs. To the
end, we used the DFG-in structure of a protein kinase as the
starting template, and employed the protein modeling program
Rosetta [29] to predict a large number of possible lowest-energy
conformations for its activation-loop beginning with the DFG
motif, and then selected appropriate DFG-out models according to
the space of the active-site cleft. Moreover, because in the process
of the DFG-flip, significantly conformational changes not only
occur in the activation-loop, but also in the N-lobe, especially in
helix aC [10,11,30], to mimic such conformational change, the N-
lobes of some DFG-in kinases were rotated about a pre-defined
axis before the phase of the activation-loop remodeling, and the
rotational angles were determined by the criteria obtained by the
analysis of the existing kinase structures. To test the quality of the
obtained DFG-out models, we predicted the binding modes for the
known type-II inhibitors (Table 1) based on these models, and the
results were in very good agreement with the X-ray crystal
structures. Also, we tested the abilities of these models to recognize
their corresponding type-II inhibitors by screening a small-
molecular database which contains about 750 protein inhibitors,
including the known type-II inhibitors (see Table S1 in Supporting
Information). Results showed that the predicted DFG-out models
were selective toward their specific type-II inhibitors. All these
results suggested that the presented computational approach
would have practical applications in the structure-based design
and screening of novel type-II kinase inhibitors.
Results and Discussion
Outward movements of N-lobes in DFG-out structures
We searched the Protein Dada Bank (PDB) at the beginning of
this study and found seven kinases with both the DFG-in and
DFG-out structures, as listed in Table 1. To prepare the starting
all-atom structures for the structural prediction afterwards, we
used the program Rosetta to relax the obtained X-ray crystal
DFG-in structures. Then we aligned these relaxed structures with
the DFG-out structures and found that the N-lobe conformations
in the DFG-out structures of some kinases are different from their
corresponding conformations in the DFG-in structures. As
illustrated in Fig. 1A, the N-lobe of the LCK DFG-out structure
moves more outward than that of the relaxed DFG-in structure,
and leads to a wider active-site cleft. It appears that in these
kinases a sufficiently wide pocket between the N-lobe and C-lobe is
required for the DFG-flip and the binding of the type-II ligands
[10,11,16]. In contrast, in the crystal DFG-in structures, part of
the N-lobe such as the helix aC usually moves inward to the
active-site cleft to form a more compact conformation and leads to
a narrow cleft.
To deeply understand the differences between the DFG-out and
DFG-in conformations, we further examined the outward
movements of the N-lobes in the mentioned structures and found
that such structural changes could be attributed to rotations of the
N-lobes around an axis. As indicated in Fig. 1B, the rotation axis is
perpendicular to the plane which is defined by the center of the
kinase catalytic domain and the start and end residues of the helix
aC, and roughly passes through the residue in the middle of the
hinge region which links the N-lobe to the C-lobe. With respect to
the relaxed DFG-in structures, the N-lobes in the DFG-out
structures rotate around the defined axis about 5,15 degrees
(Table 1). To quantitatively characterize the space of the active-
site cleft induced by the N-lobe rotations, we used the sum of 4
pairwise distances among four conserved residues. These four
residues are Lys273 (LCK numbering, see PDB code: 3LCK) of
the b-sheet and Glu288 (LCK numbering) of the helix aC, which
form a conserved salt-bridge, and Asp and Phe of the DFG-motif
(see Fig. 1A). And the 4 pairwise distances are those from Lys273
to Asp, Lys273 to Phe, Glu288 to Asp, and Glu288 to Phe,
respectively. If the sum of these 4 distances is less than 30 A ˚, the
cleft space is considered to be too small; the space is thought large
Table 1. DFG-in structures of protein kinases for DFG-out conformation prediction.
Kinases
PDB codes of DFG-in
structures and chain IDs
PDB codes of type-II inhibitors and corresponding
PDB codes of kinases in the DFG-out conformation
ABL1 2F4J(A) 406(2E2B), 7MP(2HIW), GIN(2HZ0), KIN(2HZN), PRC(1FPU), STI
(1IEP, 1OPJ, 2HYY)
BRAF1 2FB8(A,B) BAX(1UWH, 1UWJ)
EPHA3 2QOQ(A) IFC(3DZQ)
KIT 1PKG(A,B) STI(1T46)
LCK 3LCK(A) 1N8(2OG8), 242(2OFV), 9NH(3B2W), STI(2PL0)
MK14 1M7Q(A) 1PP(2BAJ), AQZ(2BAK), B96(1KV2), BMU(1KV1), L09(1WBN),
L10(1W82), L11(1W83), LI2(1WBS), LI3(1WBV), WBT(1WBT)
SRC 1Y57(A) STI(2OIQ)
doi:10.1371/journal.pone.0022644.t001
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22644Figure 1. Analyses of kinase DFG-out structures. (A) Superposition of the DFG-in and DFG-out structures of LCK (PDB codes: 3LCK and 2PL0,
respectively), and the conserved residues that characterize the space of the active-site cleft (LCK numbering: K273, E288, D382, and F383). (B) Rotation
axis of the N-lobe shown by the LCK DFG-in structure. (C) Superposition of the LCK DFG-out structure and the DFG-in structure with the rotated N-
lobe. (D) Analyses of the active-site cleft of the kinase ABL1 DFG-out structure (PDB code: 2F4J) using the programs PASS and LIGSITE. The three red
spheres B1,B 2, and B3 represent the three binding site centers identified by PASS. The grid points enclosed with the gray mesh represent the cleft
binding pocket identified by LIGSITE.
doi:10.1371/journal.pone.0022644.g001
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and 32 A ˚ suggests that the cleft just needs a slight enlargement.
Based on the above observations, we divided the N-lobe rotations
of DFG-in structures into three categories: no rotation for the sum
greater than 32 A ˚, rotations by 5 degrees for the distance sum
between 30 A ˚ and 32 A ˚, and 15 degrees for the sum less than
30 A ˚ (Table 2). And after the rotation, the N-lobe conformations
of the starting structures are very similar to those in the DFG-out
structures with type-II ligands, as illustrated in Fig. 1C.
To further analyze the volumes of the active-site clefts in the
known DFG-out kinases, we also used the program PASS [31] to
investigate the potential binding sites in the active-site cleft. The
PASS results showed that there exist three binding pockets in the
active-site clefts of the DFG-out structures. For example, in Fig. 1D
the centers of the three pockets in the ABL1 DFG-out structure
(PDB code: 2F4J) are shown as red spheres, B1,B 2 and B3,
respectively. These three pockets were also defined as adenine
pocket, hydrophobic pocket II and DFG-out pocket, respectively,
in the study by Ranjitkar et al. [18] (see figure 1B in this reference).
To quantitatively define these three pockets, we also used the
program LIGSITE [32] to calculate the numbers of 1 A ˚-grid
points in the pockets. The numbers of the LIGSITE grid points in
the pockets are related to their volumes. For the sake of intuition,
we simply transformed the numbers of the grid points into the
numbers of water molecules in a density of 1 g?ml
21: any water
molecule was considered as non-occupied if its nearest distance to
the grid points of the three pockets is large than 1.6 A ˚. The
numbers of the occupied water molecules in the mentioned
pockets for some known DFG-out structures were listed in Table 3.
Note that, some crystal DFG-out structures in Table 1 lacked
certain atomic coordinates in their activation-loops, and thus their
data of occupied water molecules are not presented in Table 3.
Again, the numbers of occupied water molecules in Table 3
indicate that a wide active-site cleft is crucial for the specific
binding of type-II inhibitors to the DFG-out conformation of a
protein kinase. In other words, a type-II inhibitor which is able to
simultaneously bind to the three pockets in the DFG-out
conformation should possess a scaffold of certain volume and
length, as indicated by Ranjitkar et al. [18].
Predictions of kinase DFG-out models
For each protein kinase listed in Table 1, we employed the
ALRM approach illustrated in Fig. 2A to generate 200 lowest-
energy models using its corresponding DFG-in structure, and then
classified them into DFG-in or DFG-out models according to the
method described in Materials and Methods. As indicated in
Table 4, about 31–55% of the lowest-energy models were found to
be in the DFG-out conformations. Like other proteins, kinases are
dynamic macromolecules which are able to explore multiple
conformations via internal motions. As pointed out by Aleksan-
drov and Simonson [33], according to equilibrium statistical
mechanics even the highest energy conformations of an apo-kinase
have non-zero populations. Thus, the high percentages of the
lowest-energy models with the DFG-out conformation imply that
certain low-energy DFG-out conformations might be sampled
dynamically by the kinase. In fact, the crystal structures of kinases
in complex with type-II inhibitors have already implied that
multiple DFG-out conformations do exist at physiological
conditions and may be trapped and stabilized by the inhibitors
[34]. Of course, whether the DFG-out conformations could stay
stable or just transiently exist remains an open question, and
further investigations by other approaches beyond the scope of this
study are needed, such as by molecular dynamics (MD) simulation.
It is well known that the activation-loops of PKs are flexible
segments. Indeed, this flexibility is also the reason why in a lot of
crystal structures of PKs the atomic coordinates of the part or
whole activation-loop were unable to be solved. Also, flexibility
means that the activation-loops may explore multiple conforma-
tions in a dynamic way and possess certain conformational
diversity, for example, the activation-loop of ABL1 in the DFG-
out conformation has been observed to adopt two very different
conformations (see details in PDB codes: 1FPU and 2HZ0). To
characterize such conformational diversity, we performed cluster-
ing analysis using the MaxCluster program (see http://www.sbg.
bio.ic.ac.uk/,maxcluster/index.html) based on the activation-
loop conformations in the DFG-out models. We used MaxCluster
because it was able to effectively deal with the conformational
comparison of short segments among proteins, e.g., the activation-
loops. To carry out the conformational comparison required for
clustering, we considered a segment of sixteen residues which starts
from the second preceding residue of the DFG motif and covers
Table 2. Three categories of the N-lobe rotations in the DFG-
in structures.
Rotation states Kinases
Distance sum of four
conserved residues (A ˚)
No rotation (D.32 A ˚) ABL1 32.8
MK14 36.7
5 degrees (30#D#32 A ˚) EPHA3 30.5
SRC 30.9
15 degrees (D,30 A ˚) BRAF1 25.7
KIT 22.6
LCK 28.5
doi:10.1371/journal.pone.0022644.t002
Table 3. Numbers of occupied water molecules in the active-
site clefts of kinase DFG-out structures in complex with type-II
inhibitors.
Kinases PDB codes
Numbers of occupied
water molecules
ABL1 1FPU 46
1IEP 49
1OPJ 50
2HIW 41
2HYY 43
2HZ0 33
2HZN 45
KIT 1T46 43
LCK 2PL0 45
MK14 1W82 44
1W83 35
1WBN 45
1WBS 44
1WBT 42
1WBV 39
2BAJ 44
doi:10.1371/journal.pone.0022644.t003
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conformations of this segment in the DFG-out models, the
predicted DFG-out models of the studied kinases were then
clustered using the nearest neighbor clustering algorithm with an
RMSD (root mean square deviation) threshold of 4 A ˚, and the
populations of the major conformational clusters with members
not fewer than 5 are listed in Table 4.
As seen in Table 4, for all 7 kinases the numbers of major DFG-
out activation-loop clusters are about 2–4. This implies that the
activation-loops of these kinases possess certain flexibility, in
agreement with the experimental observation that one kinase can
access multiple inactive conformations [10,34]. To demonstrate
this conformational diversity, the representative conformations of
the major clusters of each kinase in Table 4 are illustrated in Fig. 3.
As shown, the activation-loops of ABL1, BRAF1, KIT, LCK and
SRC may adopt more different conformations, while those of
EPHA3 and MK14 adopt fewer. The conformational diversity of
the activation-loops may be attributed to the central and C-
terminal parts of the loops, and the N-terminal parts are relatively
stable. This is reasonable because the central and C-terminal parts
of the activation-loops are more exposed to the solvent. The
cluster populations in Table 4 also reveal an interesting fact that
there exists a large cluster (i.e., the first cluster) in each kinase
which contains more than 50% of the DFG-out models, and thus
the populations of the other clusters are relatively small. Since the
DFG-out models were obtained by independent Rosetta runs, the
large population of the first cluster might imply that the
conformations in this cluster are the most probable DFG-out
conformations of the kinase. Of course, due to the transient nature
of the DFG-out conformations, many of them may not be
observed directly, and those in the crystal structures appear to be a
few probable DFG-out conformations which were trapped and
stabilized by the type-II inhibitors.
To examine the relationship between the predicted DFG-out
models and the corresponding crystal DFG-out structures, we also
carried out structural comparison in two different ways: global
comparison which focuses on the whole structure using the TM-
align program [35], and local comparison which focuses on the
DFG motif using the MaxCluster program. Results of the TM
scores and the heavy-atom RMSDs of the DFG motifs are listed in
Table 4. Results in Table 4 show that TM-scores are all greater
than 0.85, indicating that the predicted DFG-out models as a
whole are very similar to the crystal structures in complex with the
type-II inhibitors. This is attributed to that, with respect to the
crystal structures, in the DFG-out models no significant confor-
mational change occurs in the C-lobes, and the N-lobes essentially
maintain the scaffolds similar to those in the crystal structures.
On the other hand, as seen, for the local comparison of the
DFG motifs the average RMSDs are in the range from 4.0 to
6.0 A ˚. Again, this indicates the conformational diversity of the
activation-loops, and demonstrates that the ALRM approach
could sample multiple DFG-out conformations without bound
type-II inhibitors. Despite of the conformational diversity, the
minimum RMSDs were found to be below or around 2.0 A ˚, and
the superposition of the predicted DFG motifs with the minimum
RMSDs against the crystal structures indicated that the predicted
models are in good agreement with the crystal structures (Fig. 4).
This suggests that the DFG-out conformations close to those in the
crystal structures could be sampled by the ALRM approach.
Because the conformation of the DFG motif is the major site
targeted by the type-II inhibitors, and also vital for the formation
of a wide active-site cleft, the ability of the ALRM approach to
generate conformations of which DFG motifs are similar to those
in the crystal structures shows its potential for design and discovery
of the type-II inhibitors.
Thus, our ALRM approach based on the DFG-in structures
could predict multiple DFG-out conformations of protein kinases
reliably. Compared with the DOLPHIN model [28], our method
deletes no residues and the DFG-out models possess all atomic
coordinates of the activation-loop residues. Also, as indicated by
Table 4, our approach is able to sample possible DFG-in and
DFG-out conformations of a kinase, and therefore mimics the
dynamic conformational ensembles of the kinase. The ability of
the current approach to sample a large number of possible
activation-loop conformations ensured us to generate certain
DFG-out conformations which may be targeted by specific type-II
inhibitors. Recently, it has been shown that the DFG-flip from the
DFG-in to DFG-out conformations could also be triggered
through MD simulation [11]. However, because the flip appears
Figure 2. The activation-loop remodeling method (ALRM) and
the vitual molecule defined for selecting the DFG-out models.
(A) Flowchart of the ALRM approach. (B) The structure of the virtual
molecule that resembles the minimum core scaffold of typical type-II
inhibitors.
doi:10.1371/journal.pone.0022644.g002
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process at the atomic level needs long time-scale calculations.
Compared to the MD simulation, the current approach is faster
when sampling a large number of possible conformations. And this
is also important for the practical applications in the structure-
based drug design and discovery.
Because in the ALRM approach the numbers of the obtained
DFG-out models are in the range of tens to hundreds, in practice it
becomes important to select a small number of models for
molecular docking in order to reduce computational cost. Of
course, in principle one could use all predicted DFG-out structures
in the binding pose prediction and virtual screening. However, as
mentioned, known type-II inhibitors were found to occupy three
potential pockets (i.e., adenine pocket, hydrophobic pocket II and
DFG-out pocket) in the DFG-out conformations and thus possess
relatively large scaffolds. For example, the molecular weights of
the known type-II inhibitors in Table S1 of Supporting
Information are in the range from 287 to 594. It is obvious that
DFG-out structures with small active-site clefts could not
accommodate large type-II molecules. To avoid unnecessary
Figure 3. Representative DFG-out models of the major activation-loop clusters. (A) ABL1. (B) BRAF1. (C) EPHA3. (D) KIT. (E) LCK. (F) MK14.
(G) SRC.
doi:10.1371/journal.pone.0022644.g003
Table 4. The percentages of DFG-out models, populations of major activation-loop clusters, TM-score values and heavy-atom
RMSDs of DFG-motif with respect to the corresponding crystal structures.
Kinases
PDB codes of
DFG-out
structures
Structural
resolution (A ˚)
Numbers and
percentages of
DFG-out models
Populations of
DFG-out clusters
$5 Global TM-score DFG motif RMSD (A ˚)
Average Maximum Average Minimum
ABL1 1FPU 2.40 104 (52%) 52, 20, 10, 6 0.86 0.89 4.48 1.64
BRAF1 1UWH 2.95 67 (34%) 41, 13, 5, 5 0.87 0.88 4.45 1.45
EPHA3 3DZQ 1.75 101 (51%) 68, 17, 7 0.90 0.91 5.71 1.51
KIT 1T46 1.60 67 (34%) 39, 12, 6, 5 0.88 0.90 5.39 2.03
LCK 2PL0 2.80 102 (51%) 56, 21, 7, 6 0.89 0.92 4.59 1.98
MK14 1WBT 2.00 61 (31%) 41, 9 0.95 0.97 5.02 2.03
SRC 2OIQ 2.07 109 (55%) 56, 23, 11, 7 0.96 0.97 2.75 0.60
doi:10.1371/journal.pone.0022644.t004
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this study we only selected the DFG-out structures with large
active-site clefts.
As discussed in the last subsection, typical type-II inhibitors
possess a scaffold of certain volume and length in order to
simultaneously bind to the three pockets of the DFG-out
conformation as shown in Fig. 1D. Thus, inspired by the study
of Ranjitkar et al. [18], we derived a virtual molecule which
roughly resembles the minimum core scaffold of typical type-II
inhibitors (Fig. 2B). By using the same way to calculate the volume
of active-site cleft as described in the next subsection, we found
that this virtual molecule occupies a space of about 20 water
molecules. Thus, after several preliminary tests, we eventually used
the criterion of 20 occupied water molecules for DFG-out model
selection: only those models satisfying the selection criterion were
chosen to form a DFG-out conformation ensemble. On average,
the numbers of the selected DFG-out models for the kinases in
Table 1 are about 10, and therefore the computational costs are
significantly reduced as compared to the use of all the predicted
DFG-out conformations. Note that, in the following virtual
screening the use of DFG-out structures with large active-site
clefts does not eliminate small-sized compounds in consideration.
In fact, both small-sized and large-sized compounds were fully
considered when using the DFG-out structures with large clefts,
because these structures could accommodate not only large-sized
compounds, but also small-sized compounds whose volume is
smaller than 20 occupied water molecules.
Binding pose predictions of the known type-II inhibitors
As mentioned, a potential application of the predicted DFG-out
models in the structure-based drug design is to predict the binding
modes of type-II inhibitors to protein kinases. To explore such a
possibility, we performed molecular docking with the known type-
II inhibitors using the selected DFG-out models as the receptors.
Molecular docking with the program AutoDock (Version 4.2)
[36,37] was carried out for the inhibitor-kinase complexes listed in
Table 5. The molecular structures of these type-II inhibitors are
listed in Table S1 of Supporting Information.
For each inhibitor, molecular docking to all selected models in
the DFG-out ensemble of the given kinase was first conducted with
AutoDock, and then the predicted binding poses were extracted
and analyzed by this procedure: the docking poses outside the
active-site clefts of all selected DFG-out models were ruled out at
first; then, the remaining poses in all selected DFG-out models
were ranked according to their docking energies; finally, the
lowest-energy pose was treated as the representative pose of this
inhibitor, and the corresponding DFG-out model bound by the
representative pose of the inhibitor was regarded as the
representative DFG-out conformation of the kinase. Consequent-
ly, the representative pose of the ligand for each inhibitor-kinase
complex was compared to that in the corresponding crystal
structure, and the results of the heavy-atom RMSDs are listed in
Table 5.
Table 5 shows that the RMSD values of the lowest-energy poses
with respect to those in the crystal structures are below or around
2A ˚, the usual RMSD criterion for determining the quality of
predicted poses with respect to the crystal structures. By a careful
analysis of all the docking poses, we found that for almost all
inhibitors the binding poses could be classified roughly into 2
major clusters: poses in one cluster are similar to that in the
corresponding crystal structure and thus possess small RMSD
values, and poses in the other cluster have an opposite orientation
to that in the crystal structure and therefore possess large RMSD
values. As indicated by RMSDs in Table 5, except in one kinase-
ligand pair (i.e., ABL1-PRC), the predicted lowest-energy poses of
the ligands were found to have the same orientations as those in
the crystal structures. Thus, the predicted orientations of the type-
II inhibitors were in very good agreement with those in the crystal
structures, with a success rate close to 96%. This can also be seen
in the superposition of the lowest-energy poses of type-II ligands
with their crystal structures (Fig. 5). Since in the molecular docking
simulations the protein flexibility for a given DFG-out model was
not considered, this could cause errors in the binding pose
predictions. For example, for several kinase-ligand pairs, although
the orientations of the lowest-energy poses of the ligands were the
same as those in the crystal structures, their RMSD values are
Figure 4. Superposition of DFG motifs in the DFG-out models with respect to those in the crystal structures. (A) ABL1. (B) BRAF1. (C)
EPHA3. (D) KIT. (E) LCK. (F) MK14. (G) SRC.
doi:10.1371/journal.pone.0022644.g004
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docking poses possessing similar orientations as those in the crystal
structures. Results for the poses with the minimum RMSDs are
given in Table 5. As seen, about 83% of the minimum RMSDs are
less than 2.0 A ˚. Again, this indicates that the molecular docking
approach in this study could reliably predict the binding poses of
type-II inhibitors to protein kinases.
To further examine the reliability of the docking procedure
using the DFG-out models, we also perform docking using the
crystal structures listed in Table 1 as the receptors, with the same
protocol as described in above. The RMSDs of the lowest-energy
binding poses are given in Table 5. Except for ABL1-KIN and
LCK-9NH, most of the lowest-energy poses are in good
agreement with those in the crystal structures. Especially, the
RMSD values of twenty lowest-energy poses are smaller than
2.0 A ˚. This number is the same as that of the minimum RMSDs
using the DFG-out models. These results not only demonstrate
that the employed docking procedure based on AutoDock 4.2 is
reliable, but also suggest that the DFG-out models are valid for
type-II inhibitor docking.
As mentioned, the RMSDs of several lowest-energy poses in
Table 5 are greater than 2.0 A ˚.F o re x a m p l e ,f o rk i n a s eL C K
even the minimum RMSDs are close to or greater than 2.0 A ˚.
Comparing the bound DFG-out models with the corresponding
crystal structure, we found that the relatively large RMSDs were
mainly caused by different conformations of residue Met292 in
the DFG-out models and the crystal structure (PDB code:
3LCK). In the DFG-out models, the side-chain of Met292
usually extends towards the hydrophobic pocket II and thus
hinders the binding of the ligands to the optimal position. In
contrast, in the crystal structure, the side-chain of Met292
adopts a different orientation to leave enough space for the
inhibitor binding (Fig. 6A). Besides, other factors may also affect
the binding poses, such as the conformation of the Lys273-
Glu288 salt bridge etc. The residue Glu288 usually forms two
hydrogen bonds with the Lys273 and the type-II inhibitors,
respectively, to stabilize the binding poses. So either the steric
effect or the missing hydrogen bonds may affect accuracy of the
binding pose prediction. To overcome such a problem, in the
future it seems we need a method combining the current
approach with MD simulation in order to account for additional
small-scale motions in the kinase-inhibitor complex obtained by
AutoDock, like the MD refinements of the docked HIV-1
protease-inhibitor complexes [38,39].
Table 5. RMSDs of the lowest-energy representative poses of type-II inhibitors with respect to those in the crystal structures using
DFG-out models and crystal structures, respectively.
Kinases Type-II ligands Based on DFG-out models Based on crystal structures
RMSD of the lowest-energy pose (A ˚) Minimum RMSD (A ˚) RMSD of the lowest-energy pose (A ˚)
ABL1 406 1.73 1.30 1.13
7MP 2.05 0.75 0.96
GIN 2.59 1.21 0.84
KIN 1.49 0.71 9.91
a
1.47
b
PRC 9.57
a 0.85 2.08
1.48
b
STI 2.78 2.51 0.54
BRAF1 BAX 1.77 1.77 1.04
EPHA3 IFC 1.88 1.69 1.05
KIT STI 1.94 1.76 0.99
LCK 1N8 2.00 1.95 1.11
242 1.97 1.68 0.99
9NH 2.27 2.16 6.40
STI 2.56 2.21 1.16
MK14 1PP 1.42 1.42 1.50
AQZ 1.93 1.93 2.36
B96 2.17 2.17 1.15
BMU 1.34 1.34 0.87
L09 1.69 1.69 1.67
L10 1.47 1.47 0.66
L11 1.63 1.54 1.73
LI2 1.34 1.13 1.53
LI3 0.68 0.62 1.29
WBT 1.47 1.44 1.61
SRC STI 1.94 1.88 1.28
aThe lowest-energy poses possess an opposite orientation with respect to those in the crystal structures, and therefore have large RMSDs.
bThe minimum RMSDs of binding poses other than the lowest-energy poses.
doi:10.1371/journal.pone.0022644.t005
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bound by the type-II inhibitors and the key residues in the active-
site clefts affecting the binding pose are in their optimal positions,
the docking energies of the lowest-energy poses obtained by these
structures could be used as a reference to validate the AutoDock
docking energies based on the DFG-out models. The correlation
Figure 5. Superposition of the predicted binding poses of type-II ligands with respect to those in crystal structures for 24 known
kinase-inhibitor pairs.
doi:10.1371/journal.pone.0022644.g005
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crystal structures is illustrated in Fig. 6B. As seen, most of the
docking energies of the lowest-energy poses based on the DFG-out
models correlate well with those based on the crystal structures. In
Fig. 6B, there exists a systematic shift of ,2.0 kcal/mol between
the docking energies based on the DFG-out models and those
based on the crystal structures. Such an energy shift might be
attributed to that not all the residues of the DFG-out models are in
their optimal positions for the binding of the inhibitors, because
the DFG-models were generated with the ALRM approach
without any bound inhibitors, and in the docking process, the
DFG-out models were set as rigid receptors. Recently, studies have
shown that there exist certain differences between the predicted
binding free energies and the observed energies of the type-II
inhibitors [28,33], and this is mainly because in molecular docking
many factors affecting the observed binding free energies were
neglected, such as population differences between the DFG-out
and DFG-in conformations in solution [18]. Nevertheless, to a
certain extent the good correlation between the docking energies
using the DFG-out models and those based on the experimental
structures indicates that the docking procedure itself is reliable,
and the AutoDock score could be used to rank the docking poses
based on the DFG-out models. Of course, further analysis is
needed to find out the exact differences between the AutoDock
energies and the observed energies.
Virtual screening of type-II inhibitors using the DFG-out
models
To test whether the predicted DFG-out models are applicable to
virtual screening of the type-II inhibitors, we carried out a virtual
screening study using the ensembles of DFG-out models and a
database of about 750 known protein inhibitors commercially
available from MERCK (i.e., Calbiochem inhibitor database). The
Calbiochem inhibitor database is a collection of various potein
inhibitors, and its details can be seen in Inhibitor SourceBook (2rd
Edition) by MERCK. The inhibitor files suitable for molecular
docking were downloaded from a homepage of ZINC website [40]
at http://zinc.docking.org/vendor0/index_fsm.shtml (Please see
the item related to Calbiochem on this page). To test whether the
DFG-out models can recognize their specific type-II ligands, the
inhibitors listed in Table S1 were also included into the screening
database. Because the molecular size in the screening database
may have effects on the study, we calculated the molecular weights
of the database inhibitors and compared them with those of the
known type-II inhibitors. The molecular weights of the inhibitors
in the database are in the range from 100 to 550, and the
distribution is shown in Figure S1 in Supporting Information.
Meanwhile, the molecular weights of the known type-II inhibitors
in Table S1 of Supporting Information are in the range from 280
to 594. Thus, there is no significant difference in the molecular size
between the dataset and the known type-II inhibitors.
In the virtual screening for a given kinase target, molecular
docking was performed for each inhibitor in the database against
every model in the DFG-out ensemble of the given kinase. The
representative for a given inhibitor was selected by the same
procedure as described in the binding pose predictions of known
type-II inhibitors: the lowest-energy pose of the ligand in all DFG-
out models was used as the binding representative of the inhibitor
to the kinase target. Eventually, all inhibitors for the given kinase
target were re-ranked by the docking energies of their represen-
tatives to form a hit list from the lowest-energy inhibitor to the
highest-energy inhibitor. Based on the obtained hit lists, AUC
(area under ROC curve) values which characterize the virtual
screening performance were calculated, as shown in Fig. 7.
As seen in Figs. 7A–G, all the AUC values of the target kinases
are greater than 0.90. Such high AUC values indicate that the
predicted DFG-out models are selective toward their specific type-
II inhibitors. Indeed, all the known type-II inhibitors were found
to be ranked in the top 1–5% in their hit lists. More importantly,
consistent with the results of binding pose prediction in Table 5,
the binding poses of the top-ranked hits were also similar to those
in the crystal structures. Therefore, these results illustrate that the
computational approach and protocols presented in this study are
very promising for structure-based screening of novel type-II
inhibitors of protein kinases.
As mentioned, in the past there were few effective methods able
to identify the type-II inhibitor targeting a specific DFG-out
Figure 6. Docking pose with a relatively large RMSD and correlation of docking energies. (A) Steric clash in the DFG-out models of LCK.
(B) Correlation of the docking energies based on the DFG-out models with those based on the crystal structures.
doi:10.1371/journal.pone.0022644.g006
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we employed a conformational selection procedure that used an
ensemble of DFG-out conformations in the binding pose
predictions and virtual screening. In this approach, as the
representative binding pose of the ligand was identified, the
DFG-out conformation in complex with the representative pose
was determined, too. The results of the binding pose predictions
and virtual screening demonstrate that the conformational
selection protocols developed in the study are effective for the
identification of the DFG-out conformation targeted by specific
inhibitors. From the viewpoint of dynamic conformational
ensembles of proteins, we may consider this procedure as the
process that the given type-II ligand selects its most favorite DFG-
out conformation [41]. If one postulates that the DFG-in and
DFG-out conformations of a protein kinase are populated (i.e.,
pre-existing) in solution, in general, different ligands may bind to
and stabilize different populated DFG-in and DFG-out confor-
mations, e.g., different ABL1 inhibitors [25]. So there is no doubt
that the conformational selection procedure using a representative
ensemble of DFG-out conformations would be a more effective
way to discover specific kinase inhibitors than using only one
DFG-out conformation. Thus, computational approaches for
reliably predicting kinase DFG-out structures are valuable for
the structure-based drug design and discovery of protein kinase
inhibitors.
Conclusion
In this study, we have developed a computational approach
for predicting the inactive DFG-out conformations of protein
kinases using the existing DFG-in structures, and developed
conformational selection protocols for the applications of the
predicted DFG-out models in the binding pose prediction and
v i r t u a ls c r e e n i n go ft h et y p e - I Ii n h i b i t o r s .U s i n gt h eD F G - o u t
models, we predicted the binding poses for the known type-II
inhibitors, and the results were found to be in good agreement
with the X-ray crystal structures. Also, we tested the abilities of
the DFG-out models to recognize their corresponding type-II
inhibitors by screening a database of small molecules. The AUC
results indicated that the predicted DFG-out models are selective
toward their specific type-II inhibitors. Therefore, these results
illustrate clearly that the computational approach and protocols
presented in this study are very promising for the structure-based
design and screening of novel type-II inhibitors targeting protein
kinases.
Figure 7. Performance of virtual screening for type-II inhibitors using the predicted DFG-out models, as shown by the AUC (area
under curve) values. (A) ABL1. (B) BRAF1. (C) EPHA3. (D) KIT. (E) LCK. (F) MK14. (G) SRC.
doi:10.1371/journal.pone.0022644.g007
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Preparation of the DFG-in structures
The DFG-in structures for the DFG-out conformation predic-
tions were downloaded from the Protein Data Bank. For each
kinase structure, ions and small molecules including water were
first deleted. Then, if the kinase possesses phosphorylated groups,
those groups were mutated into the original non-phosphorylated
amino-acids using the homology-modeling program MODELLER
[42], and if there were missing atoms in the PDB files, the
coordinates of the missing atoms were also added by standard
modeling procedure with MODELLER. Then, the DFG-in
structures were refined by using the high-resolution protocols
implemented in the Rosetta program [29]. Finally, the distance
sum of the four conserved residues (LCK numbering: Lys273,
Glu288, Asp and Phe of the DFG-motif, see PDB code: 3LCK)
was calculated, and the N-lobe of the kinase domain was rotated
according to the degree values defined in Table 2.
Activation-loop remodeling
To predict the DFG-out conformation, activation-loop remod-
eling of the DFG-in structure was performed using the rebuilding-
and-refinement protocols implemented in the ‘loop_relax’ sub-
routine of the Rosetta program [43]. Fragment files, loop
definition file and other parameters needed for running the
Rosetta program were created and defined according to the
protocols. The loop segment for the modeling was defined to start
with the second N-terminal residue ahead of the DFG motif, and
end at the last C-terminal residue of the activation-loop. We used
the most hydrophilic residue located in the middle part of the
defined loop segment as the cut point. The cyclic coordinate
descent (CCD) method was used to maintain the chain
connectivity of the loop segment in the modeling process [44].
After the loop segment rebuilding, all-atom refinement procedure
was employed to refine the side chains of the activation-loop
rebuilding model and thereby obtain the final all-atom lowest
energy conformation. For each kinase, 200 all-atom lowest energy
models were generated by independent runs. The whole
procedure for predicting one all-atom model took approximately
3–4 CPU hours on a usual Intel Pentium IV processor. And all the
model computations were conducted on the MagicCube super-
computer in Shanghai Supercomputer Center, China.
Conformational classification of predicted models
The obtained models were first classified into DFG-in, DFG-out
and intermediate conformations by the following vector-based
method. This method is based on that before and after the DFG-
flip process the Asp and Phe residues are always located on two
opposite sides of the activation-loop (Fig. 8A). Thus, by aligning
the obtained model against the starting DFG-in structure, if the
Asp and Phe residues of the model is on the same sides of the
corresponding residues of the DFG-in structure, that model would
be considered as a DFG-in model; if the situation is just opposite,
that model would be classified into the class of the DFG-out
conformations. All other models are classified as the intermediate
conformations. To the end, four atoms of the DFG-motif were
selected from each aligned structure, Cc and Ca atoms of Asp, Ca
and Cc atoms of Phe, and labelled as R1, R2, R3 and R4 for the
atoms of the starting DFG-in structure, and R’1, R’2, R’3 and R’4
of the obtained model, respectively. Then, eight vectors are
defined as (Figs. 8B and C):
r21~R1{R2, r23~R3{R2, r32~R2{R3, r34~R4{R3 ð1Þ
r’21~R’1{R’2, r’23~R’3{R’2, r’32~R’2{R’3, r’34~R’4{R’3ð2Þ
By cross products of these vectors, four new vectors are derived as:
p1~r21|r23, p2~r34|r32; ð3Þ
p’1~r’21|r’23, p’2~r’34|r’32: ð4Þ
If the directions of the vectors p1 and p2 are opposite, the point
multiplication of the two vectors is negative. Therefore, after
aligning a predicted model against the starting DFG-in structure, if
p1:p’1v0 and p2:p’2v0, this model is a DFG-out model; if
p1:p’1w0 and p2:p’2w0, this model is considered as a DFG-in
model. Other models are treated as models in the intermediate
state of the DFG-flip.
Selection of DFG-out models for molecular docking
To select appropriate DFG-out models for molecular docking,
the classified DFG-out models were analyzed by the programs
PASS [31] and LIGSITE [32], in order to identify the putative
binding sites in the active-site cleft, and characterize the volumes
of the binding pockets. To ensure that the active-site cleft is large
enough for accommodating a type-II inhibitor, only those DFG-
out models with at least three binding sites identified by PASS in
the active-site cleft were first selected. These selected models were
then analyzed with the program LIGSITE to find out the actual
volumes of their active-site clefts. LIGSITE determined the pocket
space by calculating the numbers of 1 A ˚-grid points in the active-
site cleft, and the number of the grid points is related to the pocket
volume. For the sake of intuition, the number of the grid points
was transformed into the number of water molecules in the density
of 1 g?ml
21 in the cleft: any water molecule was considered as
non-occupied as its nearest distance to the grid points of the three
pockets was greater than 1.6 A ˚. To ensure the finally selected
models possessing an active-site cleft with certain space, we
employed a number of occupied water molecules more than 20 as
the criterion to select the final DFG-out models to form the
ensemble of DFG-out conformations for molecular docking.
Ensemble docking of the DFG-out models
AutoDock program (Version 4.2) with the Lamarckian genetic
algorithm [36,37] was used for the molecular docking in the binding
pose prediction and virtual screening. We used the central binding site
B2 identified by the program PASS as the center of the grid box for
docking, see Fig. 1D. And the size of the grid box is 60660660 A ˚.
Twenty docking runs of a ligand were carried out for each DFG-out
conformation of the target kinase. To conduct the Lamarckian genetic
algorithm, a population of 150 random ligand conformations in
random orientations and at random translations was first generated,
and then the population evolved according to the algorithm and
terminated after 27,000 generations and a maximum of 1,500,000
energy evaluations. Eventually, for a given pair of ligand and the DFG-
out conformation, the docking yielded 20 docked poses. Other
necessary parameters for docking were set to the default values
provided by AutoDock. After the docking for all DFG-out models of
the ensemble was completed, all the docking poses for the given kinase-
ligand pair were collected and analyzed by the following protocol of
docking pose analysis.
Analysis of docking poses
The docking poses of a ligand against all DFG-out models in the
ensemble of a target kinase were extracted and analyzed. Any docking
ð2Þ
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binding site points B2,B 3(see Fig. 1D) was less than 3 A ˚ was considered
as outside the active-site cleft and ruled out at first. The remaining
poses from all DFG-out models were then ranked according to their
docking energies. The lowest-energy pose was treated as the
representative pose of the ligand, and the corresponding DFG-out
model in complex with the ligand representative was considered as the
representative DFG-out model.
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